Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 30, 2024Cancer MedicineOpen Access

Assessment of prolonged proteasome inhibition through ixazomib‐based oral regimen on newly diagnosed and first‐relapsed multiple myeloma: A real‐world Chinese cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

ALAijun LiuHYHong YuRHRui Hou

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Liu et al. (2024) studied this question.

synapsesocial.com/papers/68e6ca9bb6db64358764933dhttps://doi.org/10.1002/cam4.7177
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In-class transition from bortezomib to ixazomib-based regimens in transplant-ineligible patients with newly diagnosed multiple myeloma: A retrospective, observational, real-world study conducted in China2025
  2. 2Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China2025
  3. 3Real-world efficacy and safety of ixazomib maintenance therapy in Chinese patients with newly diagnosed multiple myeloma: A multicenter retrospective study2025
  4. 4Enhancing Multiple Myeloma Treatment Outcomes with Ixazomib: Insights and Perspectives2024
  5. 5Real-world efficacy and tolerability of ixazomib-based combination therapies in advanced multiple myeloma and other plasma cell neoplasms2026